Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240


Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir.

Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD.

PLoS One. 2013 May 22;8(5):e63596. doi: 10.1371/journal.pone.0063596. Print 2013.


Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.

Velen K, Lewis JJ, Charalambous S, Grant AD, Churchyard GJ, Hoffmann CJ.

PLoS One. 2013 May 14;8(5):e64459. doi: 10.1371/journal.pone.0064459. Print 2013.


Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.

Eluwa GI, Badru T, Agu KA, Akpoigbe KJ, Chabikuli O, Hamelmann C.

BMC Clin Pharmacol. 2012 Feb 27;12:7. doi: 10.1186/1472-6904-12-7. Erratum in: BMC Clin Pharmacol. 2012;12:14. Agu, Kenneth A [added]; Chabikuli, Otto [added]; Hamelmann, Christoph [added].


Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa.

Brennan AT, Maskew M, Ive P, Shearer K, Long L, Sanne I, Fox MP.

J Int AIDS Soc. 2013 Nov 19;16:18794. doi: 10.7448/IAS.16.1.18794.


High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Skhosana L, Steegen K, Bronze M, Lukhwareni A, Letsoalo E, Papathanasopoulos MA, Carmona SC, Stevens WS.

PLoS One. 2015 Feb 6;10(2):e0118145. doi: 10.1371/journal.pone.0118145. eCollection 2015.


Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.

Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):63-70. doi: 10.1097/QAI.0b013e3181c6c65c.


Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?

Labhardt ND, Bader J, Lejone TI, Ringera I, Puga D, Glass TR, Klimkait T.

Trop Med Int Health. 2015 Jul;20(7):914-8. doi: 10.1111/tmi.12509. Epub 2015 Apr 2.


Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.

Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e68-74. doi: 10.1097/QAI.0b013e31822a9f8d.


Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.

Antinori A, Trotta MP, Nasta P, Bini T, Bonora S, Castagna A, Zaccarelli M, Quirino T, Landonio S, Merli S, Tozzi V, Di Perri G, Andreoni M, Perno CF, Carosi G.

Antivir Ther. 2006;11(2):233-43.


Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.

Wandeler G, Keiser O, Mulenga L, Hoffmann CJ, Wood R, Chaweza T, Brennan A, Prozesky H, Garone D, Giddy J, Chimbetete C, Boulle A, Egger M; IeDEA Southern Africa Collaboration.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):41-8.


Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.

Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A; UCSC cohort; MASTER cohort; ARCA cohort.

Infection. 2009 Oct;37(5):438-44. doi: 10.1007/s15010-009-8237-x. Epub 2009 Aug 7.


A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.

Saez-Llorens X, Castaño E, Rathore M, Church J, Deville J, Gaur A, Estripeaut D, White K, Arterburn S, Enejosa JV, Cheng AK, Chuck SL, Rhee MS.

Pediatr Infect Dis J. 2015 Apr;34(4):376-82. doi: 10.1097/INF.0000000000000289.


Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM.

HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255.


Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.

Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E.

HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1405-204.


Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Rosen S, Long L, Fox M, Sanne I.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):334-44. doi: 10.1097/QAI.0b013e31817ae5ef.


[To evaluate the changes in body composition in male human immunodeficiency virus-related lipodystrophy after different treatment regimens by dual-energy X-ray absorptiometry].

Zhou X, Yu W, Li T, Guo F, Lin Q, Shao H, Tian J, Xu Y, Sun P.

Zhonghua Nei Ke Za Zhi. 2014 Aug;53(8):622-5. Chinese.


High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.

Sunpath H, Wu B, Gordon M, Hampton J, Johnson B, Moosa MY, Ordonez C, Kuritzkes DR, Marconi VC.

AIDS. 2012 Aug 24;26(13):1679-84. doi: 10.1097/QAD.0b013e328356886d.


Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.

Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G; IeDEA-Southern Africa.

Clin Infect Dis. 2014 May;58(10):1473-80. doi: 10.1093/cid/ciu117. Epub 2014 Feb 27.


Renal function with use of a tenofovir-containing initial antiretroviral regimen.

Gallant JE, Moore RD.

AIDS. 2009 Sep 24;23(15):1971-5. doi: 10.1097/QAD.0b013e32832c96e9.

Supplemental Content

Support Center